Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Giovanni Bader"'
Autor:
Foteini Tsotra MPH, Ankur Malhotra MD, Platon Peristeris PhD, Ioannis Athanasiou MSc, Malina Müller PhD, Giovanni Bader MD, PhD
Publikováno v:
Inquiry: The Journal of Health Care Organization, Provision, and Financing, Vol 61 (2024)
The available evidence suggests positive health outcomes associated with early treatment intensification in Type 2 diabetes mellitus (T2DM). Our study estimated the productivity effects arising from improved health correlated with early intensified t
Externí odkaz:
https://doaj.org/article/efbcda0c519041438a368fd107b6c83a
Autor:
Michel Burnier, Shanyan Lin, Luis Ruilope, Giovanni Bader, Sharanbasappa Durg, Patrick Brunel
Publikováno v:
Blood Pressure, Vol 28, Iss 6, Pp 358-374 (2019)
Objective: Angiotensin receptor blockers (ARB) are among the recommended first-line treatment options in patients with hypertension and chronic kidney disease (CKD). This meta-analysis evaluated the effect of ARB on blood pressure (BP) and renal func
Externí odkaz:
https://doaj.org/article/37f228db1ba94e519144d17d240450ac
Autor:
Foteini Tsotra, Mathias Kappel, Platon Peristeris, Giovanni Bader, Eva Levi, Nicola Lister, Ankur Malhotra, Dennis A Ostwald
Publikováno v:
Journal of Comparative Effectiveness Research. 11:1185-1199
Aim: The current study estimates the societal impact of early intensified treatment compared with initial monotherapy with subsequent treatment intensification in newly diagnosed adults with type 2 diabetes mellitus in Mexico. Methods: An individual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf477bd83876b727a98538e623981af
https://doi.org/10.2217/cer-2022-0110
https://doi.org/10.2217/cer-2022-0110
Publikováno v:
Diabetes Obes. Metab., DOI: 10.1111/dom.14969 (2023)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510bae660822f01bf484d12d6975c6b3
https://pubmed.ncbi.nlm.nih.gov/36594703
https://pubmed.ncbi.nlm.nih.gov/36594703
Autor:
ANKUR MALHOTRA, GIOVANNI BADER
Publikováno v:
Diabetes. 71
Patients with type 2 diabetes mellitus (T2DM) are at greater risk of developing cardiovascular disease (CVD) . We aimed to explore the association between several baseline parameters and risk of cardiovascular (CV) events in patients with T2DM and wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f712f6f957a10753107eeff6d781e15
https://doi.org/10.2337/db22-748-p
https://doi.org/10.2337/db22-748-p
Publikováno v:
Diabetes. 71
The VERIFY study of primary treatment in type 2 diabetes mellitus (T2DM) , showed delayed glycemic failure (HbA1c ≥7.0% at two consecutive scheduled visits post randomization) with early combination of vildagliptin and metformin (EC) versus initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bd32690a0fa228d510bea7e8a1d8300
https://doi.org/10.2337/db22-749-p
https://doi.org/10.2337/db22-749-p
Autor:
Maria-Magdalena Balp, Matt Docherty, Andreas Tietz, Sandip K. Acharya, Giovanni Bader, Jörn M. Schattenberg, Brenda Reinhart, Juergen Loeffler, Marcos Pedrosa
Publikováno v:
Diabetes. 70
Background: Phenotypic methods such as elevated liver tests and/or the presence of obesity or hypertension are often used to identify patients with T2DM at risk for NASH. Machine learning (ML) models allow the prediction of outcomes with many interac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca857b1c93b1ef8af6908ae99860e90b
https://doi.org/10.2337/db21-1055-p
https://doi.org/10.2337/db21-1055-p
Autor:
Sharanbasappa Durg, Michel Burnier, Luis M. Ruilope, Giovanni Bader, Patrick Brunel, Shanyan Lin
Publikováno v:
Blood Pressure. 28:358-374
Objective: Angiotensin receptor blockers (ARB) are among the recommended first-line treatment options in patients with hypertension and chronic kidney disease (CKD). This meta-analysis evaluated the effect of ARB on blood pressure (BP) and renal func
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83f8a1d8c80ed0f85749a54a60c403c8
https://doi.org/10.1080/08037051.2019.1644155
https://doi.org/10.1080/08037051.2019.1644155
Publikováno v:
npj Primary Care Respiratory Medicine, Vol 28, Iss 1, Pp 1-7 (2018)
NPJ Primary Care Respiratory Medicine
NPJ Primary Care Respiratory Medicine
Glycopyrronium is a once-daily, inhaled long-acting muscarinic antagonist (LAMA) demonstrating similar efficacy to inhaled tiotropium in patients with moderate-to-severe COPD; however, the benefit of LAMAs on COPD symptoms has been variable. COPD is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f864a374bc80e2ad39a83de143b92e
http://link.springer.com/article/10.1038/s41533-018-0084-8
http://link.springer.com/article/10.1038/s41533-018-0084-8